Vlad Coric - Nov 25, 2021 Form 4 Insider Report for Biohaven Pharmaceutical Holding Co Ltd. (BHVN)

Role
Chief Executive Officer, Director
Signature
/s/ Jim Engelhart, Attorney-in-Fact
Stock symbol
BHVN
Transactions as of
Nov 25, 2021
Transactions value $
-$586,416
Form type
4
Date filed
11/26/2021, 03:28 PM
Previous filing
Jun 29, 2021
Next filing
Feb 11, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BHVN Common Shares Options Exercise $0 +11K +56.42% $0.00 30.4K Nov 25, 2021 Direct
transaction BHVN Common Shares Tax liability -$586K -5.08K -16.72% $115.55* 25.3K Nov 25, 2021 Direct F1
holding BHVN Common Shares 19.1K Nov 25, 2021 By 401(K) Plan
holding BHVN Common Shares 100K Nov 25, 2021 By The Vladimir Coric GRAT - 2019
holding BHVN Common Shares 331K Nov 25, 2021 By The Vladimir Coric Marital Trust F2
holding BHVN Common Shares 470K Nov 25, 2021 By: The Vladimir Coric Family Trust F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BHVN Restricted Share Unit Award Options Exercise $0 -11K -50% $0.00 11K Nov 25, 2021 Common Shares 11K Direct F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units.
F2 These shares are held in a trust for the benefit of the reporting person's family members, excluding the reporting person. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the inclusion of the securities held by the trust in this report and prior Section 16 filings by the reporting person is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F3 Each restricted share unit represents the contingent right to receive one common share of the issuer.
F4 The reporting person was granted 43,800 restricted share units on November 25, 2019, vesting in four equal installments on November 25, 2019, 2020, 2021 and 2022 subject to the reporting person's continued service with the issuer at each vesting date.
F5 Not applicable.